Notice: Educational content. This site contains affiliate links — we may earn a commission at no extra cost to you. Not medical advice. Consult your physician before starting any medication.
From semaglutide to tirzepatide to retatrutide — and what comes next. The complete map of your weight care journey, without marketing or hype. Clinical data, honest comparisons, and FDA approval alerts.
Phase 2 Data — NEJM 2023
Average loss at 48 weeks
(highest dose, clinical trial)
~24%
Active receptors
GLP-1 + GIP + Glucagon
3
Regulatory status
Eli Lilly · Phase 3
Pre-FDA
Estimated approval
Subject to trial results
2027
Important: Controlled clinical trial results. Individual results vary significantly. Retatrutide is NOT yet FDA-approved and NOT legally available for sale as of 2026.
Information validated against recognized medical and regulatory sources
From single-target to triple-target — each generation more effective than the last.
Trial weight-loss percentages reflect highest-dose arm at trial endpoints. Individual results vary significantly. Retatrutide is NOT yet FDA-approved and NOT legally available for sale as of 2026.
While semaglutide acts on 1 receptor and tirzepatide on 2, retatrutide is designed to simultaneously activate three key mechanisms of metabolic regulation.
Reduces appetite, slows gastric emptying, and improves insulin sensitivity. This is the mechanism of Ozempic and Wegovy.
Improves insulin response and fat utilization. This is what makes tirzepatide (Mounjaro/Zepbound) more effective than semaglutide.
Increases basal energy expenditure — the body burns more calories at rest. This is the unique piece that separates retatrutide from the rest.
Information derived from published clinical literature and manufacturer materials. This is not a claim of efficacy or therapeutic endorsement. Retatrutide is an experimental medication not approved by the FDA. Individual results vary.
11 providers compared by real cost. Subscribe for the monthly digest, or download the PDF directly.
Educational. Affiliate links. Not medical advice. No spam. Full disclosure
Key differences when considering your options in 2026.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Active receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| FDA-approved brands | Ozempic · Wegovy | Mounjaro · Zepbound | Not yet approved |
| Trial weight loss | ~15% (STEP-1) | ~21% (SURMOUNT-1) | ~24% (Phase 2) |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| 503A telehealth access | ✓ Available | ✓ Available | Coming soon |
| Telehealth cost/month | ~$179 - $349 | ~$249 - $499 | Pending launch |
Eli Lilly is advancing through regulatory phases. If you don't want to miss the day Retatrutide becomes available — or read 100 articles to understand what matters — subscribe to our exclusive alerts.
Current approval process status
Phase 1
Completed · 2022
Initial safety validated
Phase 2
Completed · 2023
~24% loss in 48 weeks
Phase 3
IN PROGRESS · 2026
Enrollment closed
NDA Submission
Estimated · 2026/2027
Formal FDA filing
FDA Approval
Estimated · 2027
Commercial availability
Phase 1 · Completed (2022)
Initial safety validated in healthy humans.
Phase 2 · Completed (2023)
~24% average loss at 48 weeks (NEJM).
Phase 3 · IN PROGRESS (2026)
Eli Lilly closed enrollment. Results expected in coming months.
NDA Submission · Pending
Formal FDA filing — estimated 2026/2027.
FDA Approval · Pending
Commercial availability estimated in 2027.
Estimated dates are projections based on Eli Lilly public statements and historical FDA review patterns. Not guarantees or official endorsements. Subject to clinical results and regulatory review timeline.
Side-by-side comparison of 11 telehealth providers (price, pharmacy, what each is best for), plus a no-spam FDA tracker — we email you the day Retatrutide gets approved and never in between unless the pipeline moves.
Free 2026 GLP-1 Cost Guide (PDF)
11 providers compared by real cost. Subscribe for the monthly digest, or download the PDF directly. No spam.
Download the PDF nowZero spam · 1-click unsubscribe · Educational content only
These are the telehealth programs we currently recommend after evaluating 11+ providers across pharmacy licensure, provider quality, transparent pricing, support depth, and regulatory standing.
Affiliate disclosure: The links below are affiliate links — we may earn a commission at no extra cost to you. Educational content only. Not medical advice. Talk to your doctor first. Full disclosure. Want the side-by-side breakdown? Read our full provider reviews →
Embody GLP1
Check the current price on Embody's site · GLP-1 gum or injection
🇺🇸 USA Certified Pharmacies · CompoundedCould suit: users who want flexibility (gum or injection) with a money-back offer advertised by Embody (check its terms). Compounded medications are NOT FDA-approved.
Visit Embody →Affiliate link — see disclosure · Educational · Talk to your doctor
Peter MD
TRT + GLP-1 + Sermorelin + NAD+ · one clinic
🇺🇸 Vero Beach, FL · Compounded 503ACould suit: men 35-55 who want testosterone + weight loss + longevity peptides under one clinician.
See Peter MD plans →Affiliate link · Educational · Talk to your doctor · Read review
SHED
All-in-One · 503A + Coaching
🆕 50 States · Bundle approachCould suit: those who want medication + coaching + supplements bundled together.
See SHED Plans →Affiliate link · Educational · Talk to your doctor
SkinnyRx
Option to consider for users
🇺🇸 Made in USA · 503A PharmacyCould suit: users comparing cost and quality.
See current offer at SkinnyRx →Affiliate link · Educational · Talk to your doctor
Eden Health
Doctor-guided GLP-1 plans
Could suit: people who want a clinician-reviewed GLP-1 plan and will confirm the price before paying.
See current Eden pricing →Affiliate link · Educational · Talk to your doctor
bmiMD
All-inclusive · 80K+ members (per bmiMD)
🇺🇸 USA · Mainstream GLP-1Could suit mainstream users seeking a tested provider with an established member base and turn-key pricing. bmiMD reports 80,000+ members; individual results vary.
See bmiMD program →Affiliate link · Educational · Talk to your doctor · Read review
Transparency: programs we evaluated and excluded
We evaluated 11+ programs and selected the six above based on regulatory standing, pharmacy licensure, provider quality, pricing transparency, and customer experience. Programs with FDA scrutiny, reported data breaches, or unclear 503A pharmacy disclosure were excluded — regardless of their commission rates. Any provider currently selling "retatrutide" is operating illegally — the medication is not yet FDA-approved.
Real costs you can expect — no hidden fees, no marketing inflation. Updated 2026.
| Provider | First Month | Ongoing /month | Includes | Type |
|---|---|---|---|---|
| Embody GLP1 NEW | Check the current price on Embody's site | Check the current price on Embody's site | GLP-1 gum option (per Embody) · HSA/FSA · money-back offer · 24/7 care-team messaging (per Embody) | Compounded |
| Eden Health | Varies (see site) | Varies (see site) | Doctor-guided GLP-1 plans · See current pricing | Compounded |
| Peter MD NEW 2026-05-21 | Check Peter MD's site for current pricing | Check Peter MD's site for current pricing | TRT + GLP-1 + Sermorelin + NAD+ · 20k+ reviews (per Peter MD) · Vero Beach FL | Compounded 503A |
| SkinnyRx | Check SkinnyRx's site for current pricing | Check SkinnyRx's site for current pricing | Medication, consultation, shipping | Compounded 503A |
| SHED NEW | Check SHED's site for current pricing | Check SHED's site for current pricing | Medication + supplements + 1-on-1 coaching · 120-day weight-loss guarantee (per SHED; conditions apply) | Compounded 503A |
| bmiMD NEW 2026-05-22 | Personalized (intake-quoted) | All-inclusive | 80,000+ members (per bmiMD) · medication + telehealth + dietary guidance · HSA/FSA | Compounded |
| Hims & Hers | ~$199 - $1,000+ | $199 (oral) / $1,000+ (Wegovy) | Medication, telehealth, app | FDA-approved |
| Wegovy direct (no insurance) | ~$1,300 | ~$1,300 | Medication only | FDA-approved |
| Zepbound direct (no insurance) | ~$1,000 | ~$1,000 | Medication only | FDA-approved |
Compounded option
SkinnyRx — quality compounded; check the current price on SkinnyRx's site.
Bundled coaching + advertised guarantee
SHED — bundles medication, supplements, and 1-on-1 coaching with a weight-loss refund guarantee that SHED advertises. Read its terms before signing up.
Insurance route
Hims & Hers — if your insurance covers Wegovy, this is the easy path.
Prices reflect publicly stated rates as of April 2026. Actual costs may vary based on dosage, location, insurance, promotions, and individual provider decisions. Confirm pricing directly with each provider before committing.
Starting a GLP-1 program via compliant telehealth in 4 honest steps.
Complete a medical questionnaire (5-8 min) about your BMI, comorbidities, and history.
A licensed physician or NP in your state reviews your case and decides if you're a candidate.
If you qualify, a 503A pharmacy prepares your medication under prescription and ships it to your home.
Virtual check-ins to adjust dosage, manage side effects, and track progress.
Retatrutide is an experimental Eli Lilly medication designed to simultaneously activate three metabolic receptors: GLP-1, GIP, and glucagon. In Phase 2 trials, it showed average weight loss near 24% of body weight at 48 weeks at the highest dose — superior to semaglutide and tirzepatide in their respective trials. It is NOT yet FDA-approved.
Eli Lilly closed Phase 3 enrollment in Q1 2026. Pharmaceutical analyst estimates place possible approval between late 2026 and end of 2027, subject to clinical results and FDA review timelines. No one can promise an exact date.
Not legally and safely. Any product sold as "retatrutide" before FDA approval is from unregulated sources and represents a serious risk to your health. If you're looking for a GLP-1 now, the legal and compliant alternatives are semaglutide or tirzepatide via licensed 503A pharmacies with valid medical prescription.
This is a personal decision between you and your physician. Some patients start with semaglutide or tirzepatide now to not lose more years of progress, with the option to transition to retatrutide if/when approved. Others prefer to wait. Our comparison can help you evaluate both routes.
Studies like STEP-1 and SUSTAIN-FORTE show that without a maintenance protocol, approximately 67% of weight is regained after stopping medication. However, programs that include behavioral coaching and maintenance protocols reduce that regain to 18-25%. The program matters more than the medication.
Compounded semaglutide and tirzepatide exist in a complex legal gray zone. Understand the rules before choosing a provider.